Nivolumab/pembrolizumab/vemurafenib
Tài liệu tham khảo
Johnson DB, et al. Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. Cancer Immunology Research 1: 373-7, No. 6, Dec 2013 - USA